Skip to main content

Table 2 Change in weight in T2DM patients with obesity (BMI > 25 kg/m2) (Intra group)

From: Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial

Parameter

Treatment

Baseline

(Mean ± SD)

Week 24

(Mean ± SD)

Change from baseline to

week 24

(Mean ± SD)

Percentage change from baseline

(Mean ± SD)

p value

Weight

Biosimilar

Liraglutide

76.4 ± 12.3

70.8 ± 19.5

5.5 ± 1.2

7.3 ± 1.7

< 0.001

Reference

Liraglutide

79.1 ± 15.2

72.1 ± 23.6

7.1 ± 2.6

8.9 ± 1.7

< 0.001